Under the agreement, PAREXEL expects to achieve cost efficiencies in its clinical development program and leverage its clinical process along with its eClinical technology platform.
The partnership model will be implemented over an 18-24 month period beginning in June 2011.
PAREXEL chairman and CEO Josef von Rickenbach said they look forward to providing innovative solutions and expertise to help Pfizer accelerate clinical trials and accomplish its development goals.
"We are focused on applying operational models, supported by a combination of our eClinical solutions and clinical processes, to help Pfizer reduce the time and cost of development," Rickenbach said.